Ablukast (INN) is an experimental drug that is a leukotriene antagonist. It was investigated for potential applications in the treatment of inflammatory conditions, including asthma, skin disorders, and inflammatory bowel disease.[1][2] It reached Phase III clinical trials, but development was discontinued in 1996.[2]
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H34O8 |
Molar mass | 498.572 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
References
edit- ^ Rosenbach T, Csatò M, Czarnetzki BM (January 1988). "Studies on the role of leukotrienes in murine allergic and irritant contact dermatitis". The British Journal of Dermatology. 118 (1): 1–6. doi:10.1111/j.1365-2133.1988.tb01743.x. PMID 2829957. S2CID 1164113.
- ^ a b "Ablukast". Adis Insight.
External links
edit- Media related to Ablukast at Wikimedia Commons